Tiny nanodevice monitors cancer treatment

A tiny nanoscale device can accurately measure a patient’s blood for methotrexate – a commonly used but potentially toxic cancer drug – in under 60 seconds, according to biomedical instrument designer Jean-François Masson, and Joelle Pelletier, a DHFR enzyme specialist, both at the Chemistry Department, University of Montreal.

Source: University of Montreal
Source: University of Montreal

Crucially, the device’s optical system can rapidly gauge the optimal dose of methotrexate a patient needs, while minimising the drug’s adverse effects.
Methotrexate can block the enzyme dihydrofolate reductase (DHFR), which is active in the synthesis of DNA precursors and thus promotes cancer cell proliferation – but it is highly toxic, so closely monitoring the drug’s concentration in a patient’s serum is vital.
Currently, a device using fluorescent bioassays to measure light polarisation produced by a drug sample is used – but this is a cumbersome, expensive platform that only experienced personnel can manipulate.

Six years ago, Pelletier and Masson investigated how to simplify the procedure. In the course of their research they developed and manufactured the miniaturised device that works by surface plasmon resonance. Put simply, it measures serum methotrexate concentration through gold nanoparticles on the surface of a receptacle. In ‘competing’ with methotrexate to block the enzyme, the gold nanoparticles change the colour of light detected by the instrument and that colour reflects the exact concentration of the drug in the blood sample.

In tests, measurements from nanoparticles device proved as accurate, Masson pointed out, yet took under 60 seconds to produce, compared to 30 minutes for current devices used, and they were obtained easily by lab technicians inexperienced in surface plasmon resonance.

The new device is small and needs little manipulation of samples, so could soon be used at the bedside and/or in a GP surgery.


More on the subject:
Read all latest stories

Related articles


RNA sequencing

Using AI to establish molecular tumor classification

Treating physicians need information about the molecular subtype of the tumor if they are to provide targeted therapy for colorectal carcinoma. A research team from University Hospital Zurich and the…


Common DNA structure

Nano-signature discovery could revolutionise cancer diagnosis

A quick and easy test to detect cancer from blood or biopsy tissue could eventually result in a new approach to patient diagnosis. The test has been developed by University of Queensland researchers…



Hackers can manipulate cancer scans

​Hackers can access a patient's 3-D medical scans to add or remove images of malignant tumors, thus placing patients at risk of misdiagnoses. The new study, published by Ben-Gurion University of…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
DiaSys Diagnostic Systems - InnovaStar

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH
Image Information Systems – iQ-4VIEW

Mobile RIS/PACS Viewer

Image Information Systems – iQ-4VIEW

IMAGE Information Systems Europe GmbH